04 Oct, EOD - Indian

SENSEX 81688.45 (-0.98)

Nifty 50 25014.6 (-0.93)

Nifty Bank 51462.05 (-0.74)

Nifty IT 41912.5 (0.36)

Nifty Midcap 100 58474.45 (-0.93)

Nifty Next 50 74620.25 (-1.10)

Nifty Pharma 23094.7 (-0.36)

Nifty Smallcap 100 18758.65 (-1.02)

04 Oct, EOD - Global

NIKKEI 225 38635.62 (0.22)

HANG SENG 22736.87 (2.82)

S&P 5807.5 (0.80)

LOGIN HERE

Amrutanjan Health Care Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 590006 | NSE Symbol : AMRUTANJAN | ISIN : INE098F01031 | Industry : Pharmaceuticals |


Chairman's Speech

Dear Valued Owners,

The key takeaway from the year in review is our return to growth! Your management team delivered a double digit growth in revenue and profit despite softened demand in our core pain relief segment.

The COVID years witnessed an above average consumption of topical pain relief products followed by a sharp decline in the years after, resulting in a build-up of channel stock, which is being gradually optimized. While there was a pronounced spike in consumption of all types of pain relievers (topical and oral), there was a noticeable shift toward oral analgesic. This trend seems to have continued during the post-COVID period till date, wherein use of tablets to relieve headaches is higher than that of balms indexed at the same level (source: IQVIA). Nevertheless, the headache relief category bounced back to high single-digit growth in the current year, and we project annualized volume and value growth for the mid-term to be in the range of 9-10%.

A compelling insight from our data reveals that headaches are experienced most by those under 30, likely a consequence of increased screen time, career pressures, and the demands of modern lifestyles. While this demographic is less inclined to use topical balms, they are showing growing interest in our Headache Roll-on—a modern, portable, and health-conscious alternative to tablets.

The topical body pain relief category is outpacing the headache relief segment, with our brands experiencing comparable growth. We are committed to dedicating resources and time to expanding our market share in this promising area.

Our women's hygiene business continues to grow in the high double-digits, owing to higher acceptance of our uniquely designed sanitary pads. The BIS standards mandated by the Government of India require certain levels of performance—which our products seamlessly meet, underscoring our commitment to consumer satisfaction.

The average temperature in India has risen by almost 0.7 degrees Celsius between 1961 and 2020 according to the World Bank Climate Change Portal, bringing with it, a myriad of health challenges to its citizens. With temperatures set to rise in the decades to come, hydration will become a critical preventive health need. The increase in number of people adopting healthy, active lifestyles is also acting as a catalyst for the electrolyte drink category. Our brand, ‘Electro+' in its ready-to-drink format, offers the highest electrolytes and energy per 200ml, complemented by palette-pleasing juice flavors.

We believe corporates have a role in reducing their carbon footprint, and to this effect, we have set goals for plastic reduction and green energy consumption.

As a value-based organization, purpose is our North star – and our selection of categories and strategies reflect this. Our CSR funds are a testament to this commitment, supporting NGOs focused on girl child education and animal welfare.

Looking ahead, our goal is not just to achieve the 10 billion milestone but to strengthen our legacy as a trusted leader in the healthcare and wellness sector. As we continue to evolve, we remain focused on delivering solutions that enhance the well-being of our consumers. Together, we will build a future where Amrutanjan stands as a reliable partner of trust in providing health and wellness products.

S. Sambhu Prasad

Chairman & Managing Director